HighTower Advisors
RXRX icon

HighTower Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

HighTower Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,500
Closed -$225 – 3943
2025
Q1 		$225 Buy
+2,500
New +$18.2K ﹤0.01% 3696
2024
Q3 		– Sell
-6,000
Closed -$164 – 3945
2024
Q2 		$164 Buy
+6,000
New +$52.3K ﹤0.01% 3624

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

HighTower Advisors's RXRX Position: Q1 2026 in Review

HighTower Advisors reduced its Recursion Pharmaceuticals (RXRX) stake by 9% in Q1 2026, selling an estimated $9.08K and leaving 23,679 shares worth $72.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3672.

HighTower Advisors first reported a position in RXRX in Q1 2024 and has held it in 9 quarters since. The position peaked at $830K in Q4 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • HighTower Advisors held 23,679 shares of Recursion Pharmaceuticals worth $72.7K as of Q1 2026.
  • HighTower Advisors sold 2,349 Recursion Pharmaceuticals shares in Q1 2026, an estimated $9.08K.
  • Recursion Pharmaceuticals made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #3672 holding.
  • HighTower Advisors first reported a position in Recursion Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • HighTower Advisors's Recursion Pharmaceuticals position peaked at $830K in Q4 2024.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.